Indegene
Indegene Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 4 strong
The short version
Indegene Limited expects organic growth in FY27 to be better than FY26, with an acceleration in the second half of FY27. Indegene expects better organic growth in FY27 compared to FY26, with acceleration in the second half of the year.
From Indegene's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Indegene Limited expects organic growth in FY27 to be better than FY26, with an acceleration in the second half of FY27.
- Best first quarter sequential growth in 4 years with a broadening client base and strong pipeline.
- The outcome-based omnichannel engagement deal starting to contribute revenues from Q3 FY27, boosting growth and profitability.
- Expansion efforts focus on deepening relationships with existing clients and converting pipeline into signed deals.
- Continued investment in Gen AI platforms embedded across operations to drive efficiency, cost reduction, and enhanced customer outcomes.
- Growth driven by broadening customer base, with active customers rising to 105 and increased revenues from accounts beyond the top 20.
2 more points from Indegene's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Indegene said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Indegene continues to invest heavily in its proprietary tech stack, including building a robust data layer integrating various data sources (Indegene data universe).
- Investments in Cortex platform for knowledge engineering, separating SME layer from technical layer to iteratively use the right AI models per use case.
- Ongoing development of agent layers (e.g., Content Super App, Medical Writing platform) to automate and scale pharma commercial and medical activities.
- Workforce transformation investments aimed at long-term employee cost optimization and managing wage hikes.
- Strategic deals such as Tectonic and large omnichannel engagements require upfront costs with revenue recognition expected in Q3 FY27 and onwards.
2 more points from Indegene's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Indegene said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Most engagements at Indegene are hybrid contracts with an early FTE component and revenue ramp-up over 3 to 4 quarters.
- A large omnichannel engagement deal (over $10 million ACV) is pure outcome-based with revenue recognition deferred by about 3 quarters, expected to start from Q3.
- Costs for this large outcome-based deal have been incurred since last quarter, implying future revenue will improve margins.
- Indegene is seeing encouraging revenue upticks shared by clients over the past 5 months.
2 more points from Indegene's call on order book
Pro opens every point from 15K+ earnings calls
Indegene — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.0K Cr, net profit ₹80 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Indegene Ltd's management said in earlier quarters
Others in Healthcare Services this season
- KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
- 3B Blackbio DX Ltd (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
- Krsnaa Diagnostics Ltd (Q1 FY27)
. Key concall takeaways from Krsnaa Diagnost.'s Q1 FY27 earnings call — and how it ranks against sector peers.
- Artemis Medicare Services Ltd (Q1 FY27)
Potential to reach INR 2,000 crores topline from Gurgaon alone within 3-5 years. Key concall takeaways from Artemis Medicare Services Ltd's Q1 FY27 earnings…
Arthneeti Pro · Annual
Indegene and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Indegene Q1 FY27 results?
Indegene Limited expects organic growth in FY27 to be better than FY26, with an acceleration in the second half of FY27. Indegene expects better organic growth in FY27 compared to FY26, with acceleration in the second half of the year.
What is Indegene share price analysis?
Indegene currently shows a below-average growth signal. The stock trades at a P/E of 32.9 with a market cap of ₹13,679 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indegene planning capital expenditure?
Indegene continues to invest heavily in its proprietary tech stack, including building a robust data layer integrating various data sources (Indegene data universe).
Keep Indegene on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.